Effects of Low-dose Infliximab on Spinal Inflammation on Magnetic Resonance Imaging in Ankylosing Spondylitis

MARTIN RUDWALEIT

J Rheumatol 2010;37;1553-1555
http://www.jrheum.org/content/37/8/1553

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Editorial

Effects of Low-dose Infliximab on Spinal Inflammation on Magnetic Resonance Imaging in Ankylosing Spondylitis

In 2003, infliximab was the first anti-tumor necrosis factor (TNF) agent to be approved by both the European Medicines Agency and the US Food and Drug Administration for the treatment of active ankylosing spondylitis (AS) that responds insufficiently to standard therapy, usually nonsteroidal antiinflammatory drugs. All initial trials in AS — whether the initial open-label studies or placebo-controlled trials — were conducted using the 5 mg/kg infliximab dosing scheme.1,2 In the placebo-controlled trial of 69 patients from Germany that led to approval of the drug, the interval between infliximab 5 mg/kg infusions was 6 weeks after the initial infusions at Week 0, Week 2, and Week 6.1 The dose and infusion interval of infliximab in AS clinical trials was chosen in analogy to the treatment schedule of infliximab in Crohn’s disease because according to the concept of spondyloarthritis as a group of interrelated diseases, Crohn’s disease appeared to be more akin to AS than rheumatoid arthritis (RA) and was the first spondyloarthropathy related disease for which approval of infliximab had been obtained. Therefore, the 5 mg/kg infliximab dose given every 6 or 8 weeks was used in the clinical trials in AS, and not the 3 mg/kg dose every 8 weeks that had been approved in RA. Unfortunately and in contrast to RA, no dose-finding studies with infliximab were ever performed in AS. Thus, from a scientific point of view we simply do not know whether infliximab 5 mg/kg every 6 weeks is the optimum treatment schedule for active AS.

In recent years a few clinical studies were published using the 3 mg/kg dose of infliximab in AS given every 8 weeks. In summary, these usually small and open-label studies revealed response rates that were similar to1,3 or lower than4 those reported from studies using the approved dosing scheme of 5 mg/kg every 6 weeks. In the context of lack of properly controlled dose-finding studies, the CANDLE trial is of interest since it was the first controlled trial, with 76 patients, assessing the efficacy of 3 infusions of infliximab 3 mg/kg given at Weeks 0, 2, and 6 in active AS versus placebo over a 12 week period, followed by an open extension phase until Week 50. The primary outcome of the CANDLE trial was the proportion of patients achieving an Assessments of SpondyloArthritis International Society (ASAS) improvement of at least 20% (ASAS20) at Week 12. ASAS20 was achieved by 53.8% of infliximab-treated patients versus 30.6% of placebo-treated patients (p = 0.042), and an ASAS40 response was achieved by 46% and 8% of infliximab and placebo treated patients, respectively (p < 0.01). However, a major clinical response defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) improvement of at least 50% (BASDAI50) was achieved by a smaller proportion of patients in CANDLE as compared to published controlled trials using the 5 mg/kg dose: Only 28% of infliximab-treated versus 11% of placebo-treated patients achieved BASDAI50 at Week 12. Therefore, 62% of patients treated with infliximab 3 mg/kg who did not reach BASDAI50 at Week 22 or Week 38 had a dose increase of infliximab to 5 mg/kg during the open-label extension period. This dose increase seemed to have benefited patients, since at Week 50 around 66% of patients treated with infliximab during the blinded phase of the study achieved BASDAI50. However, the ASAS40 response rate also increased from 46% at Week 12 to 67% at Week 50 of the open-label phase, rendering inferences about the efficacy of the dose increase difficult. Thus, from this trial we can state that the 3 mg/kg dose of infliximab is clinically effective, but we can only carefully infer that low-dose infliximab may be less effective than the 5 mg/kg dose. Unfortunately, the CANDLE trial did not directly compare infliximab at a dose of 3 mg/kg with infliximab at a dose of 5 mg/kg during the blinded phase of the study, which would have been more informative.

In the CANDLE trial the effect of low-dose infliximab (3 mg/kg) on spinal inflammation detectable by magnetic resonance imaging (MRI) was assessed in detail and is reported by Maksymowych, et al in this issue of The Journal of Rheumatology.

See Trial of low dose infliximab in AS, June 2010 and Low-dose infliximab reduces spinal inflammation in active AS, page 1728

Rudwaleit: Editorial

Downloaded from www.jrheum.org on June 25, 2017 - Published by The Journal of Rheumatology
Journal. MRI of the spine was performed at baseline and after 12 weeks in 2 out of 8 centers of the CANDLE trial. Complete MRI data were available for 32 patients (16 patients treated with infliximab and 16 patients treated with placebo). Using the Spondyloarthritis Research Consortium of Canada (SPARC) MRI index, which focuses on the 6 most affected discovertebral units (DVU), a mean reduction of active spinal inflammation by 55% was found in infliximab-treated patients after 12 weeks, whereas an increase of 6% was found in the placebo-treated AS patients, resulting in a very good Guyatt’s effect size of at least 1.7. In this MRI substudy an ASAS20 response was achieved by 68.8% of infliximab-treated versus 37.5% of placebo-treated patients (p = 0.08), ASAS40 by 56.3% versus 12.5% (p = 0.009), and BASDAI 50 by 31.3% versus 6.3% (p = non-significant), respectively.

Notably, the reduction of active spinal inflammation was independent of clinical response, i.e., independent of achievement of ASAS20 response. The uncoupling of the clinical response and reduction of MRI spinal inflammatory activity was also reported in an earlier study in 82 patients with active AS who were treated with the standard dose of adalimumab of 40 mg every other week. Also applying the SPARC system, the authors found a similar reduction of spinal inflammation of 54% after 12 weeks of adalimumab and an increase of 9% in the placebo group. Mean baseline MRI scores were similar in the adalimumab study (mean score 16.0 in the adalimumab group, 19.9 in the placebo group) and the CANDLE trial (mean score 16.4 infliximab group, 17.7 placebo group). Although direct comparison of 2 independent studies is scientifically never sound, one still gets the impression that a similar degree of reduction of MRI spinal inflammation was seen after 12 weeks with either adalimumab in standard dose or with infliximab in the 3 mg/kg dose.

In other anti-TNF studies in AS, different MRI scoring systems [usually the ASspiMRI-a (AS spinal MRI activity), score or modification thereof] and different followup periods of between 6 and 24 weeks were applied to assess the course of spinal inflammation during therapy. The shortest followup study assessed MRI after 6 weeks of etanercept in the standard dose of 25 mg given subcutaneously twice weekly. MRI spinal inflammatory activity was found to be reduced by 39.7% after only 6 weeks of etanercept. Another study on etanercept assessed MRI changes after 12 weeks and found a reduction in MRI spinal inflammatory activity of 54%. A study using infliximab 5 mg/kg also assessed MRI changes after 12 weeks and reported a reduction of MRI spinal inflammatory activity of 48%. In the large ASSERT trial in 194 patients with active AS treated with infliximab 5 mg/kg, MRI was performed after 24 weeks of therapy, with a reduction in MRI spinal inflammation of 75% (Guyatt’s effect size 1.5). The above mentioned etanercept study had another MRI assessment, also after 24 weeks, and found a reduction in inflammation of 69%. Comparing and weighing the results from these various studies using different anti-TNF agents, different scoring systems, and various followup periods is difficult. Despite these limitations, with the 3 anti-TNF agents infliximab, etanercept, and adalimumab, reductions in active spinal inflammation detectable by MRI of around 40%–70% can be observed after 6 to 24 weeks of therapy, with a tendency for a greater reduction in spinal inflammation with longer duration of therapy. Further, it seems that infliximab at a dose of 3 mg/kg as used in the CANDLE trial is very effective in reducing active spinal inflammation on MRI after 12 weeks of therapy and may be as effective as 5 mg/kg. However, we do not know the longterm effect of low-dose infliximab on spinal inflammation and a direct comparison of the low dose of infliximab of 3 mg/kg with the standard dose of 5 mg/kg on MRI spinal inflammation in AS was unfortunately not undertaken in the CANDLE trial. Given all the limitations outlined above, low-dose infliximab may suffice for the treatment of a proportion of patients and may help reduce treatment costs in AS.

The general question arises whether anti-TNF treatment for longer than 24 weeks further decreases active spinal inflammation on MRI. In this regard it is notable that in the adalimumab study no further reduction of inflammation after one year of treatment in comparison to 12 weeks was found using the SPARC system (mean score 16.0 at baseline, 6.7 after 12 weeks and 6.2 after 52 weeks). Whether this lack of further decrease in inflammation beyond week 12 is related to the anti-TNF agent adalimumab or to any other factor cannot be deduced from the available data. Similarly, in a 2-year followup study of the etanercept study, the 78% reduction (vs baseline) was not much greater than the 75% reduction observed after 24 weeks. However, the number of patients available after 2 years in this study was very small (n = 7). In contrast, in a 2-year followup study of infliximab 5 mg/kg (standard dose), a decrease of MRI spinal inflammatory activity of 69% was found at Year 2 versus 48% after 12 weeks. Thus, after 24 weeks of therapy a steady state seems to occur, with no further relevant changes in mean MRI scores, i.e., at the group level. Of importance, none of the longer followup studies reported a complete suppression of spinal inflammation in all patients: a minimal amount of active inflammation on MRI was detectable after 2 years in the etanercept study in 64% of patients, and in the infliximab 5 mg/kg study in 79% of patients. Taken together, anti-TNF therapy in AS substantially reduces spinal inflammation detectable by MRI, but continuous anti-TNF therapy appears to fail to completely abolish active inflammation on MRI. Whether the latter is related to incomplete suppression of active inflammatory sites that are already present at baseline, or whether this is due to new sites of active inflammation that arise during therapy cannot be derived from the available data.
The relation between MRI spinal inflammation and formation of syndesmophytes in AS remains to be elucidated. Followup studies suggest that new syndesmophytes potentially arise after 2 years at sites with previous active inflammation on MRI, particularly if the inflammation is no longer present after 2 years of anti-TNF therapy. However, longer followup periods with frequent MRI assessments that investigate the longer term fate of a site of active inflammation are not available. Potentially, complete suppression of inflammation — if ever achievable — may interrupt the formation of new syndesmophytes after a yet to be defined period of time of repair. Future research will hopefully teach us whether this low degree of spinal inflammation despite continuous anti-TNF therapy is the main stimulus for sustained formation of syndesmophytes in AS.

MARTIN RUDWALEIT, MD
Charité University Medicine,
Campus Benjamin Franklin,
Department of Medicine,
Berlin, Germany

Address correspondence to Dr. M. Rudwaleit, Department of Rheumatology, Ev. Krankenhaus Hagen-Haspe, Brusebrinkstrasse 20, 58135 Hagen, Germany. E-mail: rudwaleit@evk-haspe.de

The author has received speaking fees and/or honoraria for advisory board meetings from Abbott, Centocor, Schering-Plough, MSD, Pfizer, Roche, and Wyeth.

REFERENCES